EYA2 and breast cancer: One approach has already been demonstrated in a breast cancer model where a small molecule inhibited the interaction between SIX1 and EYA2, reducing downstream TGF-β signaling and EMT leading to reduced metastasis in mouse xenografts (Zhou et al., 2020).